| 标题 |
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Cancer Communications 作者:Yuankai Shi; Jin Li; Jianming Xu; Yan Sun; Li-wei Wang; et al 出版日期:2019-05-24 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)